Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2008

View Archived Issues

ABT-335 and statin combinations effective in phase III dyslipidemia studies

Heart failure model reveals novel activity of inotropic agent CK-452

Follow-up data support effect of green tea catechins in preventing prostate cancer

Oral AS-606521 inhibits uterine activity in pregnant rhesus monkeys

Takeda joins an initiative to discover biomarkers

PharmaMar's Yondelis granted orphan drug status in Switzerland, EMEA approval for phase III trial

Recent Merck & Co. patent discloses new remedial options for glaucoma

Myostatin-inhibiting gene therapy shows benefit in a mouse model of Duchenne muscular dystrophy

Chronogen patent divulges new treatment alternatives for age-related disorders

Recent Dainippon Sumitomo patent describes novel therapeutic agents for dermatitis

Carfilzomib receives FDA orphan drug designation in multiple myeloma

Eisai to resume E-2012 clinical trial in Alzheimer's disease

New antiatherosclerotic agent reported in recent Merck & Co. patent

BioMarker Pharmaceuticals launches Gene Essence genome analysis test in the U.S.

Monogram enters agreement to provide resistance and tropism testing of Progenics' PRO-140

ISTA reports results from clinical trial of once-daily Xibrom for ocular inflammation

EMEA accepts for review Cell Therapeutics' MAA for Xyotax in NSCLC

U.S. phase III clinical trial of Kamada's intravenous AAT meets primary endpoint

Cosmo begins phase I trials of anti-androgen cream as skin disorder therapy

Meda files for European approval of BioDelivery Sciences' BEMA fentanyl

Teijin enters license agreement in Japan with Dong Wha for DW-1350 in osteoporosis

ProtAffin is awarded EUR 1.1 million research grant in Austria for development of PA-401

EnVivo initiates clinical safety and biomarker study of EVP-6124 in schizophrenia

The FDA accepts FibroGen's complete response for clinical holds of FG-2216 and FG-4592

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...